This web site is not optimized for Internet Explorer 6. You may notice
decreased functionality compared to other web browsers. Please follow the
link below to upgrade to a new version of Internet Explorer.

The "Yes" link below will take you out of the Abbott Laboratories family of websites.
Links which take you out of Abbott Laboratories worldwide web sites are not under the
control of Abbott Laboratories, and Abbott Laboratories is not responsible for the
contents of any such site or any further links from such site. Abbott Laboratories is
providing these links to you only as a convenience, and the inclusion of any link does
not imply endorsement of the linked site by Abbott Laboratories.

Do you wish to leave this site?
 
Peripheral Dilatation Catheters

Armada 35 LL PTA Catheter

Indications & Important Safety Information ›› IFU (Full Version) ››
 
Overview

armada 35

 

This is Armada

Introducing Armada 35, the latest innovation from the Armada Family of PTA catheters. Engineered to treat the broadest range of lesions, with unmatched* crossing profiles and push transmission.

RANGE

Customized engineering for multiple applications

CROSS

Lowest* .035 crossing profile on the market

PUSH

Greatest* pushability on the market

 

 

*Based on balloon crossing profile measurements and pushablility performance bench tests among competitors (Powerflex® P3, Opta® Pro, Ultra-thinTM DiamondTM, Ultra-thinTM SDS, Admiral XtremeTM, Dorado®, Rival®, EverCrossTM, MustangTM)

Features

 

armada 35

armada 35

 

Low profile tip

Laser formed to enter and cross challenging lesions

armada 35

 

Responsive force transmission

Reinforced inner catheter designed for excellent pushability

armada 35

CrossFlex2 technology

Multi-layer engineering enables increased wall strength and RBPs with low crossing profiles

armada 35

Low profile rewrap

Unique balloon folding geometry minimizes profile while allowing smooth rewrap

armada 35

 

Rapid deflation

Size specific contrast lumen designed for optimal flow dynamics

Tests performed by, photos and data on file at Abbott Vascular.

Ordering Information

 

Ordering Information

BALLOON DIAMETER (mm)

BALLOON LENGTH (mm)

STOCK NUMBER CATHETER LENGTH

MIN SHEATH SIZE (F) NOMINAL PRESSURE (atm) RBP (atm)
80 (cm) 135 (cm)
4.0
150
B1040-150
B2040-150
5
8
20
4.0
200
B1040-200
B2040-200
5
8
18
4.0
250
B1040-250
B2040-250
5
8
18
5.0
150
B1050-150
B2050-150
5
8
18
5.0
200
B1050-200
B2050-200
5
8
18
5.0
250
B1050-250
B2050-250
5
8
16
6.0
150
B1060-150
B2060-150
5
6
16
6.0
200
B1060-200
B2060-200
6
6
14
6.0
250
B1060-250
B2060-250
6
6
12
7.0
150
B1070-150
B2070-150
6
6
14
7.0
200
B1070-200
B2070-200
6
6
13

 

 

AP2935518-US Rev. A

 

Indications and Important Safety Information

Top

 

Armada 35 / Armada 35 LL

PTA Catheter

 

INDICATIONS

The device is intended for dilatation of lesions in the renal, iliac, femoral, popliteal, tibial, and peroneal arteries and for the treatment of obstructive lesions of native or synthetic

arteriovenous dialysis fistulae.

This device is also indicated for stent post-dilatation in the peripheral vasculature.

 

CONTRAINDICATIONS

• Inability to cross lesion with a guide wire

• Use in the coronary arteries

 

WARNINGS / PRECAUTIONS

• This device should only be used by physicians who are experienced and have a thorough understanding of the clinical and technical aspects of PTA. • One-time use only – do not resterilize! This single use device cannot be reused on another patient, as it is not designed to perform as intended after the first usage. Changes in mechanical, physical, and/or chemical characteristics introduced under conditions of repeated use, cleaning, and/or resterilization may compromise the integrity of the design and/or materials, leading to contamination due to narrow gaps and/or spaces and diminished safety and/or performance of the device. Absence of original labeling may lead to misuse and eliminate traceability. Absence of original packaging may lead to device damage, loss of sterility, and risk of injury to patient and/or user.

• Do not use if inner package is damaged or opened.

• Employ aseptic techniques during removal from the package and during use.

• Any use for procedures other than those indicated in these instructions is not recommended.

• Use prior to the use by date.

• Carefully inspect the catheter prior to use to verify that it has not been damaged during shipment and that its size, shape and condition are suitable for the procedure for which it is to be used.

• Precautions to prevent or reduce blood clotting should be taken when any catheter is used.

• Flush or rinse all products entering the vascular system with sterile isotonic saline or a similar solution via the guide wire access port prior to use.

• Consider the use of systemic heparinization.

• When the system is introduced into the vascular system, it should be manipulated only under high quality fluoroscopy.

• The Armada 35 / Armada 35 LL PTA Catheter must always be introduced, moved and or withdrawn over a guide wire (max. 0.035”).

• Never attempt to move the guide wire when the balloon is inflated.

• Never use air or any gaseous medium to inflate the balloon.

• Do not advance the Armada 35 / Armada 35 LL PTA Catheter against significant resistance. The cause of resistance should be determined via fluoroscopy and remedial action taken.

• The minimal acceptable sheath French size is printed on the package label. Do not attempt to pass the Armada 35 / Armada 35 LL PTA Catheter through a smaller sized sheath introducer than indicated on the label.

• The size of the inflated balloon should be selected not to exceed the diameter of the artery immediately distal, or proximal, to the stenosis.

• Inflation in excess of the rated burst pressure may cause the balloon to rupture. Use of a pressure monitoring device is recommended.

• When post-dilating stents, use a balloon length that is appropriate for the deployed stent length.

 

POTENTIAL COMPLICATIONS

The following complications may occur as a result of PTA, but may not be limited to: • Abrupt closure • Access site hematoma • Aneurysm

• Angina • Arrythimias • Arteriovenous fistula • Bleeding complications which may require transfusion • Cerebral ischemia/transient ischemic attack (TIA) • Death • Embolism (air, tissue, thrombotic, systemic or device component) • Fever/pyrogenic reaction • Hypersensitivity or allergic reaction to contrast agents and drug reactions • Hypertension/hypotension • Infection • Ischemia, including tissue ischemia, steal syndrome and necrosis • Leg edema • Myocardial ischemia or infarction • Nausea and vomiting • Neuropathies or nerve injury • Occlusion • Organ failure (single, multiple) • Pain • Palpitations • Pseudoaneurysm • Renal failure/insufficiency • Restenosis

• Stroke/cerebrovascular accident (CVA) • Vascular complications, including entry site, which may require vessel repair • Vascular thrombosis • Vessel injury, e.g. dissection, perforation • Vessel spasm


Prior to use, please reference the Instructions for Use at www.abbottvascular.com for more information on indications, contraindications, warnings, precautions, and adverse events.

Top